EP Patent

EP2525812A2 — Anticoagulant antidotes

Assigned to Boehringer Ingelheim International GmbH · Expires 2012-11-28 · 13y expired

What this patent protects

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

USPTO Abstract

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Drugs covered by this patent

dabigatran-etexilate-mesylate (DABIGATRAN ETEXILATE MESYLATE)

Patent Metadata

Patent number: EP2525812A2
Jurisdiction: EP
Classification: —
Expires: 2012-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.